Literature DB >> 34283410

Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment.

Wataru Araki1, Kazutomi Kanemaru2, Kotaro Hattori3, Tadashi Tsukamoto4, Yuko Saito4, Sumiko Yoshida4, Harumasa Takano4, Masuhiro Sakata4, Yuma Yokoi4, Yoshie Omachi4, Utako Nagaoka5, Masahiro Nagao5, Takashi Komori5, Hisateru Tachimori6, Shigeo Murayama2, Hidehiro Mizusawa4.   

Abstract

OBJECTIVES: Concentrations of soluble amyloid precursor proteins-α (sAPPα) and -β (sAPPβ) in cerebrospinal fluid (CSF) may reflect the neuropathology of Alzheimer's disease (AD). We previously reported that the concentrations of both sAPPα and sAPPβ were significantly higher in patients with mild cognitive impairment (MCI) due to AD (MCI-AD) than in control subjects without cognitive impairment. The present study analyzed whether these sAPPs are useful in the differential diagnosis of MCI.
METHODS: A modified and sensitive method was used to analyze concentrations of sAPPα and sAPPβ in CSF of patients with MCI-AD (n = 30) and MCI due to other causes (MCI-others) (n = 24). Phosphorylated tau (p-tau) and amyloid β-protein 42 (Aβ42) were also analyzed using standard methods.
RESULTS: CSF concentrations of sAPPα and sAPPβ were significantly higher in the MCI-AD than in the MCI-others group (p < 0.001). Furthermore, concentrations of both sAPPα and sAPPβ were highly correlated with the concentration of p-tau, consistent with our previous report.
CONCLUSIONS: Measurement of both sAPPs in CSF using sensitive methods can be helpful in the precise differential diagnosis of patients with MCI.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Alzheimer’s disease; Biomarker; Cerebrospinal fluid; Mild cognitive impairment; Soluble amyloid precursor protein; Tau

Mesh:

Substances:

Year:  2021        PMID: 34283410     DOI: 10.1007/s40520-021-01935-7

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  26 in total

1.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

Review 3.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

Review 4.  Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.

Authors:  Sanna-Kaisa Herukka; Anja Hviid Simonsen; Niels Andreasen; Ines Baldeiras; Maria Bjerke; Kaj Blennow; Sebastiaan Engelborghs; Giovanni B Frisoni; Tomasz Gabryelewicz; Samantha Galluzzi; Ron Handels; Milica G Kramberger; Agnieszka Kulczyńska; Jose Luis Molinuevo; Barbara Mroczko; Agneta Nordberg; Catarina Resende Oliveira; Markus Otto; Juha O Rinne; Uroš Rot; Esen Saka; Hilkka Soininen; Hanne Struyfs; Silvia Suardi; Pieter Jelle Visser; Bengt Winblad; Henrik Zetterberg; Gunhild Waldemar
Journal:  Alzheimers Dement       Date:  2016-10-27       Impact factor: 21.566

Review 5.  Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.

Authors:  Anthony Fourier; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Isabelle Quadrio; Armand Perret-Liaudet
Journal:  Clin Chim Acta       Date:  2015-06-30       Impact factor: 3.786

6.  CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.

Authors:  Michael Ewers; Niklas Mattsson; Lennart Minthon; José L Molinuevo; Anna Antonell; Julius Popp; Frank Jessen; Sanna-Kaisa Herukka; Hilka Soininen; Walter Maetzler; Thomas Leyhe; Katharina Bürger; Miyako Taniguchi; Katsuya Urakami; Simone Lista; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  Alzheimers Dement       Date:  2015-03-21       Impact factor: 21.566

Review 7.  Classification and basic pathology of Alzheimer disease.

Authors:  Charles Duyckaerts; Benoît Delatour; Marie-Claude Potier
Journal:  Acta Neuropathol       Date:  2009-04-21       Impact factor: 17.088

8.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

Review 9.  Advances in Alzheimer's disease drug development.

Authors:  Michael S Rafii; Paul S Aisen
Journal:  BMC Med       Date:  2015-03-25       Impact factor: 8.775

Review 10.  Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.

Authors:  Avinash Chandra; Polytimi-Eleni Valkimadi; Gennaro Pagano; Oliver Cousins; George Dervenoulas; Marios Politis
Journal:  Hum Brain Mapp       Date:  2019-09-14       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.